Park Medi World Share Price
238.05+0.00 (+0.41%)
+60.90% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
APOLLOHOSPNSE
MAXHEALTHNSE
MANIPALHOSNSE
ASTERDMNSE
FORTISNSE
MEDANTANSE
NHNSE
LALPATHLABNSE
KIMSNSE
AGARWALEYENSE
PARKHOSPSNSE
Park Medi World Share Price
238.05+0.00 (+0.41%)
+60.90% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 10% | 21% |
| - | - | 6% | 27% |
| - | - | - | - |
| 29% | 29% | 20% | 18% |
Peer Comparison
Symbol
APOLLOHOSP
MAXHEALTH
MANIPALHOS
ASTERDM
FORTIS
MEDANTA
NH
LALPATHLAB
KIMS
AGARWALEYE
PARKHOSPS
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 8,989 | ₹125737 Cr | 56.08 | 43.8 | 219.15 | ₹1942 Cr |
| 1,074.05 | ₹101061 Cr | 73.2 | 4.26 | 19.36 | ₹1442 Cr |
| 697.3 | ₹91656 Cr | 102.72 | 2.05 | 11.95 | ₹892 Cr |
| 744.6 | ₹64456 Cr | 136.94 | 3.01 | 9.46 | ₹388 Cr |
| 815.7 | ₹61061 Cr | 58.81 | 4.14 | 20.27 | ₹1042 Cr |
| 1,493.4 | ₹39740 Cr | 64.26 | 8.21 | 32.95 | ₹556 Cr |
| 1,911 | ₹38297 Cr | 44.59 | 14.73 | 71.14 | ₹806 Cr |
| 1,982 | ₹32935 Cr | 56.44 | 11.45 | 45.37 | ₹505 Cr |
| 776.8 | ₹32301 Cr | 152.07 | 1.79 | 14.23 | ₹241 Cr |
| 553.8 | ₹18439 Cr | 106.32 | 1.73 | 14.44 | ₹133 Cr |
| 237.79 | ₹10232 Cr | 39.92 | 1.21 | 7.61 | ₹258 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| ₹511 Cr | ₹476 Cr | ₹460 Cr | ₹410 Cr | ₹410 Cr | ₹399 Cr | ₹354 Cr | ₹348 Cr |
| ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹8 Cr | ₹7 Cr | ₹9 Cr | ₹15 Cr |
| ₹521 Cr | ₹483 Cr | ₹468 Cr | ₹419 Cr | ₹418 Cr | ₹406 Cr | ₹362 Cr | ₹363 Cr |
| ₹430 Cr | ₹368 Cr | ₹351 Cr | ₹326 Cr | ₹312 Cr | ₹309 Cr | ₹281 Cr | ₹280 Cr |
| ₹111 Cr | ₹134 Cr | ₹135 Cr | ₹109 Cr | ₹121 Cr | ₹112 Cr | ₹97 Cr | ₹98 Cr |
| ₹14 Cr | ₹10 Cr | ₹14 Cr | ₹15 Cr | ₹15 Cr | ₹15 Cr | ₹16 Cr | ₹16 Cr |
| ₹76 Cr | ₹105 Cr | ₹103 Cr | ₹78 Cr | ₹91 Cr | ₹82 Cr | ₹66 Cr | ₹67 Cr |
| ₹54 Cr | ₹89 Cr | ₹77 Cr | ₹53 Cr | ₹79 Cr | ₹66 Cr | ₹52 Cr | ₹46 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Revaluation reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| — | — | — | — | — |
| ₹86 Cr | ₹77 Cr | ₹77 Cr | ₹77 Cr | ₹77 Cr |
| ₹1936 Cr | ₹975 Cr | ₹806 Cr | ₹610 Cr | ₹380 Cr |
| ₹1924 Cr | ₹963 Cr | ₹794 Cr | ₹598 Cr | ₹368 Cr |
| ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr |
| ₹2022 Cr | ₹1052 Cr | ₹883 Cr | ₹687 Cr | ₹457 Cr |
| ₹82 Cr | ₹67 Cr | ₹53 Cr | ₹43 Cr | ₹87 Cr |
| ₹18 Cr | ₹384 Cr | ₹391 Cr | ₹318 Cr | ₹371 Cr |
| ₹75 L | ₹0 | ₹0 | ₹83 L | ₹83 L |
| -₹12 Cr | -₹12 Cr | -₹6 Cr | ₹49 L | ₹7 Cr |
| ₹131 Cr | ₹56 Cr | ₹51 Cr | ₹17 Cr | ₹13 Cr |
| ₹14 Cr | ₹11 Cr | ₹8 Cr | ₹5 Cr | ₹4 Cr |
| ₹153 Cr | ₹440 Cr | ₹444 Cr | ₹341 Cr | ₹396 Cr |
| — | — | — | — | — |
| ₹109 Cr | ₹136 Cr | ₹90 Cr | ₹60 Cr | ₹44 Cr |
| ₹125 Cr | ₹175 Cr | ₹175 Cr | ₹158 Cr | ₹117 Cr |
| ₹200 Cr | ₹164 Cr | ₹159 Cr | ₹155 Cr | ₹76 Cr |
| ₹96 Cr | ₹81 Cr | ₹102 Cr | ₹149 Cr | ₹116 Cr |
| ₹529 Cr | ₹557 Cr | ₹527 Cr | ₹521 Cr | ₹353 Cr |
| ₹2786 Cr | ₹2115 Cr | ₹1906 Cr | ₹1593 Cr | ₹1293 Cr |
| ₹370 Cr | ₹675 Cr | ₹734 Cr | ₹602 Cr | ₹592 Cr |
| ₹228 Cr | ₹622 Cr | ₹633 Cr | ₹557 Cr | ₹503 Cr |
| — | — | — | — | — |
| ₹1547 Cr | ₹1049 Cr | ₹1003 Cr | ₹606 Cr | ₹492 Cr |
| ₹238 Cr | ₹159 Cr | ₹166 Cr | ₹70 Cr | ₹34 Cr |
| ₹1309 Cr | ₹890 Cr | ₹837 Cr | ₹536 Cr | ₹458 Cr |
| ₹123 Cr | ₹37 Cr | ₹32 Cr | ₹5 Cr | ₹29 Cr |
| ₹13 L | ₹9 L | ₹9 L | ₹0 | ₹0 |
| ₹13 L | ₹9 L | ₹9 L | ₹0 | ₹0 |
| ₹135 Cr | ₹94 Cr | ₹75 Cr | ₹83 Cr | ₹31 Cr |
| ₹131 Cr | ₹60 Cr | ₹18 Cr | ₹108 Cr | ₹51 Cr |
| ₹1698 Cr | ₹1082 Cr | ₹963 Cr | ₹731 Cr | ₹570 Cr |
| — | — | — | — | — |
| ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹6 Cr |
| ₹593 Cr | ₹614 Cr | ₹511 Cr | ₹576 Cr | ₹449 Cr |
| ₹431 Cr | ₹361 Cr | ₹390 Cr | ₹203 Cr | ₹192 Cr |
| ₹20 Cr | ₹22 Cr | ₹14 Cr | ₹4 Cr | ₹8 Cr |
| ₹40 Cr | ₹35 Cr | ₹26 Cr | ₹77 Cr | ₹68 Cr |
| ₹1088 Cr | ₹1034 Cr | ₹943 Cr | ₹862 Cr | ₹724 Cr |
| ₹559 Cr | ₹477 Cr | ₹416 Cr | ₹340 Cr | ₹371 Cr |
| ₹2786 Cr | ₹2115 Cr | ₹1906 Cr | ₹1593 Cr | ₹1293 Cr |
| ₹47 | ₹27 | ₹57 | ₹44 | ₹29 |
| ₹47 | ₹27 | ₹23 | ₹18 | ₹12 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| ₹355 Cr | ₹286 Cr | ₹218 Cr | ₹315 Cr | ₹278 Cr |
| ₹90 Cr | ₹94 Cr | ₹139 Cr | ₹101 Cr | ₹124 Cr |
| -₹17 Cr | -₹80 Cr | ₹105 Cr | -₹118 Cr | -₹153 Cr |
| ₹428 Cr | ₹300 Cr | ₹462 Cr | ₹299 Cr | ₹250 Cr |
| ₹329 Cr | ₹215 Cr | ₹361 Cr | ₹199 Cr | ₹155 Cr |
| -₹333 Cr | -₹100 Cr | -₹255 Cr | -₹234 Cr | -₹248 Cr |
| ₹121 Cr | -₹89 Cr | -₹130 Cr | ₹1 Cr | ₹163 Cr |
| ₹116 Cr | ₹26 Cr | -₹23 Cr | -₹34 Cr | ₹70 Cr |
| ₹103 Cr | ₹77 Cr | ₹100 Cr | ₹151 Cr | ₹81 Cr |
| ₹17 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹237 Cr | ₹103 Cr | ₹77 Cr | ₹117 Cr | ₹151 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Park Medi World Share Price
238.05+0.00 (+0.41%)
+60.90% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 3 out of 9 oscillators
RSI
44.56Sell
STOCH %K
35.04Neutral
MACD Level(12,26)
-1.58Sell
Ultimate Oscillator
56.96Buy
Aroon Oscillator
-40.00Sell
BOP
0.28Buy
CCI
-6.38Neutral
Williams %R
-64.96Neutral
Momentum
14.18Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 7 out of 9 moving averages
EMA 9
242.64Sell
SMA 9
247.98Sell
EMA 21
243.35Sell
SMA 21
238.01Buy
EMA 50
251.12Sell
SMA 50
253.96Sell
EMA 200
234.72Buy
SMA 200
246.63Sell
WMA 20
243.63Sell
Pivot
Pivot
Classic
Resistance 5
263.85
Resistance 4
257.26
Resistance 3
250.67
Resistance 2
244.08
Resistance 1
240.58
Pivot
237.49
Support 1
233.99
Support 2
230.90
Support 3
224.31
Support 4
217.72
Support 5
211.13
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Park Medi World Share Price
238.05+0.00 (+0.41%)
+60.90% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|
| 82.90% | 82.89% | 82.89% | 82.89% |
| 0.88% | 0.82% | 0.86% | 1.28% |
| 2.58% | 3.06% | 3.33% | 3.41% |
| 5.39% | 5.66% | 5.62% | 5.17% |
| 8.25% | 7.57% | 7.30% | 7.25% |
Bulk & block deals
Name
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|
Insider trading & SAST
Client name
Kotak Mahindra Mutual Fund
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 Apr 2026 | Other | Acquisition | 0.04 | 5.03 | 0 | — | 1.75 L | 11 Mar 2026 | Market | 2,17,66,377 | SAST | 29(1) | — |
Park Medi World Share Price
238.05+0.00 (+0.41%)
+60.90% past 1 Year
Park Medi World, along with its subsidiaries, is in the business of owning, managing and running medical facilities in order to provide comprehensive services and to undertake research including clinical
Corporate Actions
Date
Type
Details
Company details
Park Medi World Share Price
238.05+0.00 (+0.41%)
+60.90% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Park Medi World Share Price
238.05+0.00 (+0.41%)
+60.90% past 1 Year
News
1 of 20
Stock NewsPARKHOSPS19 Nov 2026
Park Medi World has maintained its FY27 revenue target at approximately Rs 2,050 crores, supported by existing hospitals and the ramp-up of newer facilities. Management expects improving EBITDA margins as the Agra, Panchkula, and Rudrapur hospitals mature.
In H1 FY27, the company reported revenue of Rs 987 crores, up 22% year on year. The 14 established hospitals generated Rs 915 crores of revenue and Rs 234 crores of EBITDA, while the three new hospitals contributed Rs 72 crores of revenue and recorded an EBITDA loss of Rs 6 crores. New units are expected to become profitable within approximately 12 to 15 months.
The company has indicated an FY27 EBITDA expectation of approximately Rs 540 to Rs 550 crores. It also plans to add 2,300 beds by December 2028, taking total capacity to 6,590 beds, with estimated expansion capex of Rs 750 crores. The planned capacity additions could support revenue growth and market share, although near-term margins may remain affected by start-up losses at new hospitals.
Park Medi World - Quaterly Results
ResultPARKHOSPS13 Nov 2026
NULL
Park Medi World informs about outcome of board meeting
Stock NewsPARKHOSPS13 Nov 2026
NULL
Park Medi World reports Profit after tax of Rs -65.70 Lakhs, in the September 2026 quarter
ResultPARKHOSPS13 Nov 2026
NULL
Park Medi World Reports Lower Q2 EBITDA And Margin Year On Year
ResultPARKHOSPS13 Nov 2026
Park Medi World Limited, operator of Park Hospitals, reported Q2 EBITDA of Rs 101 crores, compared with Rs 113 crores in the corresponding quarter of the previous year, indicating a year on year decline of 10.6%. EBITDA margin decreased to 20% from 27.5% year on year, a contraction of 750 basis points.
Revenue, PAT, quarter on quarter comparisons, analyst consensus estimates, and management commentary were not provided in the available update. The reported decline in EBITDA and operating margin indicates weaker quarterly operating performance compared with the year-ago period. Park Medi World Limited is listed on NSE under the symbol PARKHOSPS and operates in the healthcare sector.
Park Medi World Reports Lower Q2 Profit Despite Stronger Revenue Growth
Stock NewsPARKHOSPS13 Nov 2026
Park Medi World Limited reported consolidated second-quarter net profit of Rs 52.10 crores, declining from Rs 73.60 crores in the corresponding year-ago quarter. Consolidated revenue increased to Rs 510.00 crores from Rs 410.00 crores year on year, indicating stronger operating scale despite weaker profit conversion.
The 31.25 percent decline in net profit alongside 24.39 percent revenue growth points to pressure on margins or higher costs during the quarter. The available update does not provide details on EBITDA, finance costs, exceptional items, segment performance, management changes, or shareholder distributions. Park Medi World operates in healthcare services and trades on the NSE under the symbol PARKHOSPS.
The earnings update is likely to weigh on near-term sentiment because profit declined materially even as revenue expanded. No same-day stock-price reaction was provided.
Income Tax Department Searches Park Medi World Corporate Premises
Stock NewsPARKHOSPS14 Oct 2026
The Income Tax Department conducted searches involving Park Medi World Limited, which operates in the hospital and healthcare services sector. The available update does not disclose the locations searched, the reason for the action, the entities or individuals covered, or whether any documents, assets, or undisclosed income were identified.
No quantified financial impact, regulatory order, management change, corporate action, or earnings revision has been reported in the available information. The development may create near term uncertainty around compliance, potential tax exposure, and management attention, but the effect on earnings, leverage, and market share cannot be assessed without further official disclosures.
Park Medi World signs long-term asset-light hospital operations deal in Kanpur
Stock NewsPARKHOSPS16 Sept 2026
Park Medi World Ltd has entered into a long-duration agreement with Axis Educational Society for the operation and management of a 300-bed hospital in Kanpur. The deal spans 28 years and is structured on an asset-light model, under which Park Medi World will focus on running and managing the facility without heavy incremental ownership of physical hospital infrastructure. The agreement explicitly covers renovation and modernization of the existing hospital premises, indicating planned upgrades in clinical facilities, patient amenities and possibly medical equipment over the tenure of the contract.
An asset-light operating framework typically allows healthcare operators to expand their managed bed capacity while limiting capital expenditure intensity, which can support return ratios and scalability over time. By securing the long-term management mandate for a 300-bed hospital, Park Medi World potentially enhances its presence in the Uttar Pradesh healthcare market and broadens its regional footprint. The Kanpur facility, once renovated and modernized, may contribute to incremental patient volumes and service offerings, which in turn could support revenue growth and operating leverage for the company over the life of the agreement. The 28-year horizon provides extended visibility on operational control and potential cash flow generation from this location.
The collaboration with Axis Educational Society also underscores the trend of healthcare companies partnering with educational and charitable trusts to run hospitals under professional management contracts. While specific financial terms, expected annual revenue contribution, margin profile and capex commitments have not been disclosed in the available context, the structure suggests that major upfront infrastructure ownership costs may rest primarily with the asset owner, with Park Medi World focusing on clinical operations, management expertise and efficiency improvements. No immediate information is available in the given text regarding any contemporaneous movement in the share price of Park Medi World Ltd or changes in leverage ratios associated with this agreement.
Park Medi World sets up SPV unit for Prayagraj 550 bed hospital PPP project
Stock NewsPARKHOSPS31 Aug 2026
Park Medi World has set up a unit for a special purpose vehicle linked to the Prayagraj 550 bed hospital public private partnership project. The development indicates that the company is moving ahead with project specific execution through a dedicated structure, which is typically used to ring fence cash flows, project obligations, and operating risks tied to a single asset or contract.
The disclosure is relevant for monitoring future order conversion, project implementation timelines, and the eventual scale of operating contribution from the hospital project. No additional financial details, equity stake, capex quantum, or commissioning schedule were provided in the available update.
Park Medi World bags PPP contract for 550-bed Prayagraj hospital
Stock NewsPARKHOSPS26 Aug 2026
Park Medi World Ltd has secured a public-private partnership (PPP) contract to develop and operate a new 550-bed hospital in Prayagraj, Uttar Pradesh. The company plans to invest around Rs 200 crores in this greenfield healthcare infrastructure project. Construction of the hospital is targeted to be completed within two years, after which Park Medi World will operate the facility under a long-duration 45-year operation lease. The project structure indicates significant long-term visibility of operating revenues once the asset is commissioned.
The addition of a 550-bed facility meaningfully expands the company’s hospital network capacity and strengthens its presence in North India, with a specific focus on a key urban centre in Uttar Pradesh. The PPP framework with a state authority typically provides stability of tenure and can support better asset utilisation through a mix of government and private patient flows, though actual financial benefits will depend on the detailed concession terms, tariff structure and payor mix. The planned capex of around Rs 200 crores will increase the company’s capital employed over the medium term and may elevate leverage during the construction and initial ramp-up phase. However, once operational, the incremental bed capacity and associated services could enhance scale, support higher operating leverage and potentially improve market share in the regional healthcare services market. The two-year construction timeline means that near-term earnings impact is limited to capex and financing outflows, with operating contributions expected only post commissioning and subsequent ramp-up of occupancy levels.
Park Medi World plans bed expansion to 5,740 by March 2028
Stock NewsPARKHOSPS3 Aug 2026
Park Medi World said its Managing Director and Chairman expects the company to end FY27 with 4,740 beds and plans to add 1,000 more beds by FY28, taking total capacity to 5,740 beds by March 2028.
The update points to continued network expansion in the healthcare business, with the additional capacity likely supporting patient volumes and longer-term operating scale. The announcement is an operating guidance update rather than a financial result, and no information was provided on capex, funding, occupancy, revenue contribution, or margin impact.
For the stock, the development is relevant as a capacity-led growth signal for Park Medi World, but the immediate market effect is difficult to quantify from the available information alone.
Park Medi World acquires Mehar Hospital in Zirakpur from Mehar Mediserve
Stock NewsPARKHOSPS3 Aug 2026
Park Medi World has announced the acquisition of Mehar Hospital, located in Zirakpur, from Mehar Mediserve LLP. The transaction represents a strategic expansion of Park Medi World’s hospital portfolio, strengthening its presence in the regional healthcare market. While the exact deal value, bed capacity of Mehar Hospital, and funding structure have not been disclosed, the acquisition is likely aimed at enhancing Park Medi World’s service offerings and geographic reach in Northern India. By integrating Mehar Hospital’s existing operations, clinical infrastructure, and patient base, Park Medi World could potentially benefit from operating synergies, better utilisation of medical staff, and improved overhead absorption across its network.
From an earnings perspective, incremental revenue from Mehar Hospital may support top-line growth for Park Medi World over the medium term, depending on how quickly the acquired facility’s capacity is ramped up and aligned with the parent company’s standards of care. The deal may also help Park Medi World improve its competitive positioning versus other regional hospital chains and standalone nursing homes, particularly if it introduces higher-margin specialties or upgrades diagnostic and surgical capabilities at the Zirakpur facility. However, integration-related costs, refurbishment capex, and any potential increase in leverage cannot be assessed at this stage in the absence of transaction details. No immediate information is available on stock price reaction, regulatory approvals, or changes in management structure linked to the acquisition. Overall, this development is a routine but strategically positive corporate action for Park Medi World within the healthcare services space.
Park Hospitals to acquire Mehar Hospital, Zirakpur for Rs 107 crores cash deal
Stock NewsPARKHOSPS3 Aug 2026
Park Hospitals (Park Medi) has announced a corporate acquisition of Mehar Hospital located in Zirakpur for a total cash consideration of Rs 107 crores. The transaction falls under strategic expansion in the healthcare services space, adding a new hospital asset to Park Hospitals’ network through a 100 percent cash-funded deal. The use of cash rather than equity suggests the company is deploying internal accruals or available liquidity instead of diluting existing shareholders, which may have implications for near-term leverage and cash flows depending on its current balance sheet strength. By acquiring Mehar Hospital, Park Hospitals is positioned to expand its regional footprint in North India, potentially increasing patient volumes, bed capacity and medical service offerings in the Zirakpur and adjoining markets. This could support future revenue growth and operating scale benefits once integration is completed and capacity utilisation improves. The size of the transaction at Rs 107 crores indicates a meaningful asset addition relative to typical single-hospital acquisitions in tier-2 urban clusters, and may help the company consolidate its presence against local competitors and strengthen referral networks with nearby cities. From an earnings perspective, performance will depend on Mehar Hospital’s existing occupancy, case mix, and margin profile, as well as Park Hospitals’ ability to optimise costs, enhance clinical specialities and improve pricing and payor mix post-acquisition. There is no immediate information on regulatory approvals or closing timelines, but hospital acquisitions of this nature typically require standard regulatory, licensing and operational clearances before full integration. No stock price reaction or market trading data is available in the given context, so immediate secondary market impact cannot be assessed.
Park Medi World Q1 revenue rises to Rs 476 crores
ResultPARKHOSPS3 Aug 2026
Park Medi World reported Q1 revenue of Rs 476.00 crores versus Rs 460.00 crores in the same quarter last year, reflecting a year on year increase of about 3.5%.
Only revenue was provided in the context. EBITDA, PAT, and margin data were not disclosed, so they are left out of this summary. The update indicates steady top line growth for the quarter, but there is not enough information here to assess operating efficiency, net profitability, or a full earnings beat versus expectations.
Park Medi World Q1 EBITDA rises year-on-year with stable margins
ResultPARKHOSPS3 Aug 2026
Park Medi World has reported a healthy improvement in operating performance for the latest first quarter, led by a year-on-year increase in EBITDA and broadly stable margins. Q1 EBITDA stood at Rs 126.00 crores compared with Rs 105.00 crores in the same quarter last year, indicating a solid expansion in operating profitability in absolute terms. This growth in EBITDA reflects improved operating leverage and better cost absorption across the company’s healthcare operations, even though detailed revenue and PAT figures are not available in the provided context.
On the margin front, Park Medi World’s Q1 EBITDA margin came in at 26.53%, marginally higher than 26.3% in the year-ago period. This slight uptick in margin suggests that the company has managed to maintain cost discipline and pricing strength, allowing it to convert higher operating scale into incremental margin improvement rather than sacrificing profitability. The combination of stronger EBITDA and a stable-to-improving margin profile is typically viewed as operationally positive, especially in the hospital and healthcare services segment where fixed costs are significant and capacity utilisation plays a key role in earnings trajectory.
While revenue, PAT, and quarter-on-quarter comparisons are not disclosed in the given information, the available data points underline a period of robust operating performance for Park Medi World. The improvement in EBITDA, with only a modest yet positive change in margins, may support investor confidence in the company’s near-term earnings outlook, provided broader sector and macro conditions remain supportive. No street consensus, management commentary, or stock price reaction details are mentioned in the context, so the assessment remains focused purely on the reported operating metrics.
Park Medi World Q1 consolidated net profit rises strongly on YoY basis
ResultPARKHOSPS3 Aug 2026
Park Medi World has reported a strong improvement in profitability for the latest reported quarter, with Q1 consolidated net profit coming in at Rs 82.50 crores versus Rs 57.90 crores in the same quarter last year on a YoY basis. This represents a solid increase in profit, indicating better performance at the bottom line compared with the prior year period. The growth in consolidated net profit suggests that the company has either managed to improve its operating efficiency, contain costs, or benefit from stronger demand conditions in its core healthcare services, although detailed drivers are not specified in the available context. The higher profit figure on a consolidated basis also implies improved contribution from subsidiaries or related entities included in the group’s financials.
The disclosure focuses on profit after tax, and specific data for revenue, EBITDA, and margin trends are not provided, so a detailed assessment of operating performance, net margin expansion, or contraction is not possible from the given information. Similarly, there is no mention of QoQ comparisons, street expectations, or consensus estimates, making it difficult to judge whether the result is a formal beat or in line with market forecasts. There is also no factual management commentary, guidance, or indication of strategic initiatives accompanying these numbers in the context shared. Market reaction in terms of share price movement or changes in trading volumes for PARKHOSPS on NSE/BSE is not available, so the immediate impact on the stock cannot be quantified. Nonetheless, the significant YoY increase in consolidated net profit is an objectively positive earnings data point for Park Medi World and may be viewed constructively by market participants tracking the company’s quarterly performance.
Park Medi World unit clears Gurugram Park Hospital Platinum 100-bed expansion plan
Stock NewsPARKHOSPS30 Jun 2026
Park Medi World, through its unit Umkal Health Care, has approved an expansion project for its Park Hospital facility in Gurugram, Haryana. The plan involves adding 100 new beds to the existing hospital infrastructure, taking the total bed capacity of this location to 750 beds upon completion. The upgraded facility will be branded as Park Hospital Platinum, indicating a premium positioning within the company’s hospital network and potentially targeting higher-yield specialties and patients. The commissioning of the expanded facility is expected by November 2026, aligning with the company’s broader capacity expansion roadmap across North India. This incremental capacity directly enhances Park Medi World’s ability to serve a larger patient base in the Gurugram market, which is a key cluster for the group’s operations.
From an earnings perspective, the additional 100 beds, once operational and ramped up, should support higher revenues from in-patient services, ancillary diagnostics, and surgical procedures, subject to effective utilisation levels and case mix. The expansion is part of a continuing strategy where the group is rapidly increasing bed capacity across its network to strengthen market share in key catchment areas and improve operating leverage. Gurugram, being an affluent and growing urban centre, offers favourable demographics for tertiary and quaternary care, which can aid faster occupancy build-up at Park Hospital Platinum. While specific capex, funding mix, and expected return metrics for this particular project are not disclosed in the provided context, the initiative is consistent with Park Medi World’s cluster-based expansion approach that aims to derive economies of scale in procurement, medical staffing, and shared services. Overall, the approved expansion reinforces the company’s growth trajectory in the hospital segment and positions the Gurugram facility as a larger, more comprehensive healthcare hub within its portfolio.
Park Medi World zooms on getting nod to acquire ‘V3 Healthcare’
Stock NewsPARKHOSPS25 May 2026
V3 Healthcare operates a multi-super speciality Hospital in the name of ‘The Medicity Hospital’
Park Medi World informs about acquisition
Stock NewsPARKHOSPS25 May 2026
NULL
Park Medi World gets nod to acquire ‘V3 Healthcare’
Stock NewsPARKHOSPS25 May 2026
V3 Healthcare operates a multi-super speciality Hospital in the name of ‘The Medicity Hospital’

